Home/Pipeline/PLD-102

PLD-102

FLT3‑mutant AML

Phase 1Active

Key Facts

Indication

FLT3‑mutant AML

Phase

Phase 1

Status

Active

Company

About PeLeMed

AI‑powered biotech delivering next‑gen FLT3 inhibitors and anti‑HBV agents for unmet oncology and viral disease needs.

View full company profile

Therapeutic Areas

Oncology Infectious Diseases